BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch

Condition studied

Folliculitis decalvans

Investigational medicinal product(s)

Eligibility

Primary endpoint

The primary endpoint is an IGA score (FD-IGA) which will be assessed by a blinded assessor. Success will be defined by at least a decrease of 2 points of the FD-IGA at 6 months.

Endpoint detail

Pain evaluated by Visual Analogue Scale (VAS) at randomization, 3, 6 and 12 months. Pain change from randomization, at 3, 6 and 12 months., Pruritus evaluated by WI-NRS (Worst Itch Numeric Rating Scale) at randomization, 3, 6 and 12 months, Quality of life evaluated by Dermatology life quality index (DLQI) at randomization, 3, 6 and 12 months, Time to first relapse during the study period, Measure of FD-IGA score in the population of patients receiving the antibiotic rescue (at the onset of the rescue), Measure of FD-IGA score (blinded assessor) at 12 months, Tolerance of drugs